Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APC-200
- Development stage
- Unknown
- Lead developer
- Adamis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
APC-200 is a first-in-class, orally administered small molecule drug that acts as a polyamine uptake inhibitor. It was initially developed by the University of Wisconsin and later advanced by Adamis Pharmaceuticals. The primary therapeutic focus for APC-200 has been prostate cancer, specifically both castrate-sensitive and castrate-resistant forms. Its mechanism involves inhibiting the cellular uptake of polyamines, which are organic cations essential for cell growth and proliferation—processes often upregulated in cancer cells. By blocking this pathway, APC-200 aims to suppress tumor progression in prostate cancer[1][2][7].
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)Polyamine transporter
Beyond the preview
Go deeper on APC-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APC-200.